| MYELODYSPLASTIC SYNDROME

Inqovi vs Reblozyl

Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.

Deep comparison between: Inqovi vs Reblozyl with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsReblozyl has a higher rate of injection site reactions vs Inqovi based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Reblozyl but not Inqovi, including UnitedHealthcare

Category

Inqovi

Reblozyl

At A Glance

RouteOral

FrequencyOnce daily, Days 1-5 of each 28-day cycle

ClassNucleoside metabolic inhibitor

RouteSC injection

FrequencyEvery 3 weeks

ClassErythroid maturation agent

Indications

MYELODYSPLASTIC SYNDROME
Refractory anemias
Refractory anemia with ringed sideroblasts
Refractory anaemia with excess blasts
Leukemia, Myelomonocytic, Chronic

beta Thalassemia
MYELODYSPLASTIC SYNDROME
Refractory anemia with ringed sideroblasts
Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Dosing

MYELODYSPLASTIC SYNDROME, Refractory anemias, Refractory anemia with ringed sideroblasts, Refractory anaemia with excess blasts, Leukemia, Myelomonocytic, Chronic 1 tablet (35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle, taken on an empty stomach; minimum of 4 cycles until disease progression or unacceptable toxicity.

beta Thalassemia 1 mg/kg SC every 3 weeks; increase to max 1.25 mg/kg if no reduction in RBC transfusion burden after at least 2 consecutive doses at 1 mg/kg.

MYELODYSPLASTIC SYNDROME (ESA-naive) 1 mg/kg SC every 3 weeks; increase up to max 1.75 mg/kg to maintain hemoglobin 10 g/dL to 12 g/dL.

Refractory anemia with ringed sideroblasts, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (ESA-refractory or intolerant) 1 mg/kg SC every 3 weeks; increase to max 1.75 mg/kg if patient is not RBC transfusion-free.

Contraindications

—

Drug Interactions

1011View drug interactions

281View drug interactions

Adverse Reactions

Most common (>=20%) fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, transaminase increased

Serious febrile neutropenia, pneumonia, sepsis

Postmarketing differentiation syndrome, interstitial lung disease, cardiomyopathy

Most common (>=10%) headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, dizziness, hypertension, nausea, edema peripheral, dyspnea, musculoskeletal pain

Serious thrombosis/thromboembolism, hypertension, extramedullary hematopoietic masses, cerebrovascular accident, deep vein thrombosis

Pharmacology

Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, causing hypomethylation and cellular differentiation or apoptosis; cedazuridine inhibits cytidine deaminase in the gastrointestinal tract and liver to increase systemic exposure of orally administered decitabine.

Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and promoting erythroid maturation by increasing late-stage erythroid precursors (normoblasts) to reduce ineffective erythropoiesis in beta-thalassemia and MDS.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Inqovi